Search

Your search keyword '"Bonichon F"' showing total 321 results
Start Over Author "Bonichon F"
321 results on '"Bonichon F"'

12. Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer Patients

Author

Schlumberger, M, Hitzel, A, Toubert, M E., Corone, C, Troalen, F, Schlageter, M H., Claustrat, F, Koscielny, S, Taieb, D, Toubeau, M, Bonichon, F, Borson-Chazot, F, Leenhardt, L, Schvartz, C, Dejax, C, Brenot-Rossi, I, Torlontano, M, Tenenbaum, F, Bardet, S, Bussière, F, Girard, J J., Morel, O, Schneegans, O, Schlienger, J L., Prost, A, So, D, Archambeaud, F, Ricard, M, and Benhamou, E

Published
2007

14. Strategie per l’ablazione con radioiodio nei pazienti con carcinoma tiroideo a basso rischio

Author

Schlumberger, M., Catargi, B., Borget, I., Deandreis, D., Zerdoud, S., Bridji, B., Bardet, S., Leenhardt, L., Bastie, D., Schvartz, C., Vera, P., Morel, O., Benisvy, D., Bournaud, C., Bonichon, F., Dejax, C., Toubert, M. E., Leboulleux, S., Ricard, M., Benhamou, E., Centanni, Marco, Del Duca, Susanna, and Tumeurs de la Thyroïde Refractaires Network for the Essai Stimulation Ablation Equivalence Trial

Published
2012
Full Text
View/download PDF

15. Diagnostic accuracy of (18)F-FDG PET/CT for the detection of peritoneal carcinomatosis of colorectal origins

Author

Bellera C, Bonichon F, Evrard S, Bullier E, Cazeau Al, Descat E, and Picat Mq

Subjects
Pathology, medicine.medical_specialty, business.industry, PET/CT, lcsh:R, peritoneal carcinomatosis, lcsh:Medicine, Diagnostic accuracy, colorectal cancer, Peritoneal carcinomatosis, Medicine, Fdg pet ct, diagnostic accuracy, business, Nuclear medicine
Abstract

Purpose: to evaluate the diagnostic accuracy of (18) F-FDG positron emission tomography/ computerized tomography (PET/CT) for the detection of peritoneal carcinomatosis (PC) of colorectal cancer (CRC). Methods: one hundred and forty six eligible patients referred for a PET/CT to evaluate CRC at a single institution were included consecutively and retrospectively. After joint training on 20 similar patient files, two nuclear physicians reviewed the PET/CT scans blindly and independently using a method specifically designed for PC detection. The gold standard was either histological results from surgical exploration for resected patients (n=65) or clinical follow up defined as the 3-month CT follow up supplemented by one year of clinical information and CT monitoring for non-resected patients (n=81). As secondary objectives we evaluated the interobserver reliability between the two PET/CT readings and the diagnostic accuracy of a contemporary ceCT (n=69) or CT component of the PET/CT (n=77) reviewed by an independent radiologist . The extent of PC according to a simplified Sugarbaker index (PCI) was examined for the operated subgroup, when PCI was available from the surgeon and PET/CT (n=12). Results: according to the gold standard, 35/146 patients had PC (including 19 of 65 patients with histological gold standard and 16 of 81 patients with clinical follow up gold standard). Sensitivity and specificity of PET/CT were 88% and 96% respectively and positive and negative predictive values and accuracy, 88%, 96% and 94% respectively. For CT alone, the corresponding values were: 68%, 92%, 72%, 90% and 86%. The interobserver agreement for the detection of peritoneal carcinomatosis in PET/CT showed high agreement at 0.91 (Kappa). Median PCI was 3 [range: 1–13] when assessed by surgeons and 4 [range: 1–10] on PET/CT. Focal uptake was the most frequently observed sign on PET. Conclusions: PET/CT appears to be an accurate and reproducible test for PC diagnosis in colorectal cancer using an interpretation method specifically designed for PC detection. To confirm these results and to evaluate peritoneal carcinomatosis extension accurately, a prospective observational study using iodine contrast-enhanced PET/CT as a first imaging technique for pre-operative staging and potentially involving further independent reviewers remains to be undertaken.

Published
2013
Full Text
View/download PDF

18. Strategies of radioiodine ablation in patients with low-risk thyroid cancer

Author

Schlumberger, M, Catargi, B, Borget, I, Deandreis, Désirée, Zerdoud, S, Bridji, B, Bardet, S, Leenhardt, L, Bastie, D, Schvartz, C, Vera, P, Morel, O, Benisvy, D, Bournaud, C, Bonichon, F, Dejax, C, Toubert, Me, Leboulleux, S, Ricard, M, Benhamou, E, and Tumeurs de la Thyroïde Refractaires Network for the Essai Stimulation Ablation Equivalence Trial

Published
2012

19. High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial

Author

Bui-Nguyen, B., Ray-Coquard, Isabelle, Chevreau, C., Penel, N., Bay, J. O., Coindre, J. M., Cupissol, D., Italiano, A., Bonichon, F., Lotz, J. P., Thyss, A., Jimenez, M., Mathoulin-Pélissier, S., Blay, J. Y., Renseigné, Non, Institut Bergogné, Department of Medical Oncology, Centre Léon Bérard [Lyon], Institut Claudius Regaud, CRLCC Institut Claudius Regaud, Centre Régional de Lutte Contre le Cancer Oscar Lambret, Centre Jean Perrin, CRLCC Jean Perrin, Institut bergogné, Centre Val d'Aurelle-Paul Lamarque, Plateforme de génétique moléculaire des cancers d'Aquitaine, Institut Bergonié - CRLCC Bordeaux, Service d'oncologie Médicale, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz, Centre Antoine Lacassagne, CRLCC Antoine Lacassagne, Unité Matériaux et Transformations - UMR 8207 (UMET), Centre National de la Recherche Scientifique (CNRS)-Université de Lille-Ecole Nationale Supérieure de Chimie de Lille (ENSCL)-Institut National de la Recherche Agronomique (INRA), Centre d'Investigation Clinique - Epidemiologie Clinique / Essais Cliniques Bordeaux, Institut National de la Santé et de la Recherche Médicale (INSERM), Eq 11, Centre Léon Bérard [Lyon]-Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Institut Bergonié [Bordeaux], UNICANCER-UNICANCER, Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Institut de Chimie du CNRS (INC)-Institut National de la Recherche Agronomique (INRA)-Centre National de la Recherche Scientifique (CNRS)-Université de Lille-Ecole Nationale Supérieure de Chimie de Lille (ENSCL), Centre Léon Bérard [Lyon]-Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lille-UNICANCER, Institut National de la Recherche Agronomique (INRA)-Ecole Nationale Supérieure de Chimie de Lille (ENSCL)-Institut de Chimie du CNRS (INC)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), and Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL)

Subjects
Male, MESH: Combined Modality Therapy, MESH: Consolidation Chemotherapy, MESH: Peripheral Blood Stem Cell Transplantation, Kaplan-Meier Estimate, Carboplatin, chemistry.chemical_compound, 0302 clinical medicine, MESH: Mesna, MESH: Carboplatin, Antineoplastic Combined Chemotherapy Protocols, Etoposide, Mesna, MESH: Etoposide, MESH: Aged, Ifosfamide, MESH: Middle Aged, Soft tissue sarcoma, Sarcoma, Hematology, Middle Aged, Chemotherapy regimen, Combined Modality Therapy, 3. Good health, Dacarbazine, MESH: Antineoplastic Combined Chemotherapy Protocols, Oncology, MESH: Young Adult, 030220 oncology & carcinogenesis, Female, medicine.drug, Adult, medicine.medical_specialty, Adolescent, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Dacarbazine, Disease-Free Survival, 03 medical and health sciences, MESH: Doxorubicin, Young Adult, medicine, Humans, Progression-free survival, MESH: Ifosfamide, MESH: Kaplan-Meier Estimate, Aged, MESH: Adolescent, Peripheral Blood Stem Cell Transplantation, MESH: Humans, business.industry, MESH: Adult, medicine.disease, MESH: Male, Surgery, Consolidation Chemotherapy, chemistry, Doxorubicin, MESH: Sarcoma, MESH: Disease-Free Survival, business, MESH: Female, 030215 immunology
Abstract

International audience; BACKGROUND: Metastatic soft tissue sarcoma (STS) prognosis remains poor and few cytotoxic agents offer proven efficacy. This randomized open phase III study examines whether high-dose (HD) chemotherapy with peripheral blood stem cells (PBSCs) could improve overall survival (OS) of chemosensitive patients. PATIENTS AND METHODS: Advanced STS patients aged 18-65 years received four courses of standard mesna, adryamycin, ifosfamide and dacarbazine (MAID) treatment. Chemotherapy-responding patients and patients with at least stable disease amenable to complete surgical resection were randomized to receive standard dose (SD) with two successive MAID cycles or HD treatments of one MAID then MICE intensification: mesna (3.6 g/m(2), day 1-5), ifosfamide (2.5 g/m(2), day 1-4), carboplatin [area under the curve (AUC) 5/day 2-4] and etoposide (300 mg/m(2), day 1-4) with PBSC reinjection at day 7. RESULTS: From 2000 to 2008, 207 patients received four cycles of MAID and 87 assessable patients were randomly assigned to receive the following: 46 SD, 41 HD, with 45 and 38 maintained for analyses after secondary centralized histological review. Futility analyses led to study closure in November 2008. Three-year OS was 49.4% for the SD group versus 32.7% for HD arm, hazard ratio= 1.26, 95% confidence interval 0.70-2.29; progression-free survival was 32.4% and 14.0%, respectively. HD treatment led to higher grades 3-4 toxicity. CONCLUSION: This study failed to show an OS advantage for advanced STS patients treated with dose-intensified chemotherapy with PBSC.

Published
2011
Full Text
View/download PDF

20. Comparison of four strategies of radioiodine ablation : final results of the randomized, prospective ESTIMABL study on 752 low-risk thyroide cancer patients

Author

Zerdoud, S., Deandreis, D., Catargi, B., Borget, I., Bastie, D., Schvartz, C., Vera, Pierre, Benisvy, D., Bournaud, C., Bonichon, F., Dejax, C., Toubert, M., Schlumberger, M., Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU), Médecine nucléaire, Département d'imagerie médicale [Gustave Roussy], and Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2011

21. Etude multicentrique de l'impact de la TEP/TDM à la fluorocholine (18F) en cas de récidive occulte de cancer de la prostate

Author

Huchet, V., Rousseau, Chloé, Brunotte, F., Olivier, P., Courbon, H., Foehrenbach, H., Bonichon, F., Garin, E., Vera, Pierre, Mundler, O., Kotzki, Pierre-Olivier, Giammarile, F., Darcourt, J., Girault, S., Baulieu, Jl, Talbot, Jn, Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU), Service de médecine nucléaire [Marseille], Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de Médecine Nucléaire [Nîmes], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Breton, Céline, Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Université Le Havre Normandie (ULH), and Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)

Subjects
ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2011

22. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer

Author

Worden, F., Fassnacht, M., Shi, Y., Hadjieva, T., Bonichon, F., Gao, M., Fugazzola, L., Ando, Y., Hasegawa, Y., do, J. Park, Shong, Y.K., Smit, J.W.A., Chung, J., Kappeler, C., Meinhardt, G., Schlumberger, M., Brose, M.S., Worden, F., Fassnacht, M., Shi, Y., Hadjieva, T., Bonichon, F., Gao, M., Fugazzola, L., Ando, Y., Hasegawa, Y., do, J. Park, Shong, Y.K., Smit, J.W.A., Chung, J., Kappeler, C., Meinhardt, G., Schlumberger, M., and Brose, M.S.

Abstract

Contains fulltext : 153920.pdf (Publisher’s version ) (Open Access), Effective adverse event (AE) management is critical to maintaining patients on anticancer therapies. The DECISION trial was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 trial which investigated sorafenib for treatment of progressive, advanced, or metastatic radioactive iodine-refractory, differentiated thyroid carcinoma. Four hundred and seventeen adult patients were randomized (1:1) to receive oral sorafenib (400 mg, twice daily) or placebo, until progression, unacceptable toxicity, noncompliance, or withdrawal. Progression-free survival, the primary endpoint of DECISION, was reported previously. To elucidate the patterns and management of AEs in sorafenib-treated patients in the DECISION trial, this report describes detailed, by-treatment-cycle analyses of the incidence, prevalence, and severity of hand-foot skin reaction (HFSR), rash/desquamation, hypertension, diarrhea, fatigue, weight loss, increased serum thyroid stimulating hormone, and hypocalcemia, as well as the interventions used to manage these AEs. By-cycle incidence of the above-selected AEs with sorafenib was generally highest in cycle 1 or 2 then decreased. AE prevalence generally increased over cycles 2-6 then stabilized or declined. Among these AEs, only weight loss tended to increase in severity (from grade 1 to 2) over time; severity of HFSR and rash/desquamation declined over time. AEs were mostly grade 1 or 2, and were generally managed with dose interruptions/reductions, and concomitant medications (e.g. antidiarrheals, antihypertensives, dermatologic preparations). Most dose interruptions/reductions occurred in early cycles. In conclusion, AEs with sorafenib in DECISION were typically grade 1 or 2, occurred early during the treatment course, and were manageable over time.

Published
2015

23. Comparison of four strategies of radioiodine ablation in patients with thyroïde cancer with low-risk of recurrence : the randomized, prospective ESTIMABL study on 753 patients

Author

Catargi, B., Borget, I., Deandreis, D., Zerdoud, S., Bridji, B., Leenhardt, L., Bastie, D., Schvartz, C., Vera, Pierre, Rohmer, V., Bussière, F., Bournaud, C., Bonichon, F., Dejax, C., Toubert, Me, Benhamou, E., Schlumberger, M., Service de médecine nucléaire [CHU Pitié-Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Université Le Havre Normandie (ULH), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA), Médecine nucléaire, Département d'imagerie médicale [Gustave Roussy], and Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR)

Subjects
[CHIM]Chemical Sciences, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2010

26. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

Author

Leboulleux, Sophie, Bastholt, Lars, Krause, Thomas, de la Fouchardiere, Christelle, Tennvall, Jan, Awada, Ahmad, Gómez, José Manuel, Bonichon, F., Leenhardt, Laurence, Soufflet, Christine, Licour, Muriel, Schlumberger, Martin Jean, Leboulleux, Sophie, Bastholt, Lars, Krause, Thomas, de la Fouchardiere, Christelle, Tennvall, Jan, Awada, Ahmad, Gómez, José Manuel, Bonichon, F., Leenhardt, Laurence, Soufflet, Christine, Licour, Muriel, and Schlumberger, Martin Jean

Abstract

No effective standard treatment exists for patients with radioiodine-refractory, advanced differentiated thyroid carcinoma. We aimed to assess efficacy and safety of vandetanib, a tyrosine kinase inhibitor of RET, VEGFR and EGFR signalling, in this setting., Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2012

27. Multidisciplinary Treatment and Survival of Patients with Vertebral Metastases from Thyroid Carcinoma

Author

Quan, GMY, Pointillart, V, Palussiere, J, Bonichon, F, Quan, GMY, Pointillart, V, Palussiere, J, and Bonichon, F

Abstract

BACKGROUND: Distant metastases from differentiated thyroid carcinoma occur in up to 20% of cases and represent the most frequent cause of thyroid cancer-related death. Metastatic disease to the spine has the potential to cause severe morbidity, including pain, neurological deficit, and paraplegia. SUMMARY: We present a case series of eight consecutive patients with symptomatic spinal metastases due to thyroid carcinoma treated by our multidisciplinary team consisting of spinal surgeons, oncologists, and radiologists, with management of each case determined by our surgical algorithm. Four patients underwent surgical decompression and stabilization for spinal metastases causing instability, spinal cord compression, neurological deficit, or intractable pain. Three patients underwent vertebroplasty for focal mechanical pain due to osteolytic metastases in the absence of significant spinal cord compression or spinal instability; one of these patients required subsequent surgical decompression for spinal cord compression. One patient was nonoperatively treated. All patients underwent total thyroidectomy for the primary cancer and adjuvant radioiodine-131 treatment. The only patient with poorly differentiated thyroid cancer, which was refractory to radioiodine-131 died at 6 months after vertebroplasty procedures for symptomatic spinal metastases. One patient with medullary thyroid carcinoma died at 18 months after vertebroplasty. All remaining six patients who had well-differentiated papillary or follicular thyroid carcinoma were alive at an average of 50 months (range: 17-96 months) after diagnosis and treatment of symptomatic spinal metastases and were ambulant, independent, and able to perform activities of daily living and had no significant pain or neurologic symptoms. CONCLUSION: The potential for long-term survival of several years following development of spinal metastases should be considered during the counseling and decision-making process for patients with thyr

Published
2012

29. Métastases pulmonaires d’origine thyroïdienne traitées par thermoablation percutanée : une option utile pour les cancers réfractaires

Author

Bonichon, F., primary, De Baere, T., additional, Godbert, Y., additional, Leboulleux, S., additional, Deschamps, F., additional, Cuinet, M., additional, Buy, X., additional, Chougnet, C., additional, Giraudet, A.L., additional, Do Cao, C., additional, Toubeau, M., additional, and Palussiére, J., additional

Published
2013
Full Text
View/download PDF

41. Recommandations pour la prise en charge des tumeurs stromales gastro-intestinales

Author

Le Cesne, A., primary, Landi, B., additional, Bonvalot, S., additional, Monges, G., additional, Ray-Coquard, I., additional, Duffaud, F., additional, Bui Nguyen, B., additional, Bugat, R., additional, Chayvialle, J.A., additional, Rougier, P., additional, Bouché, O., additional, Bonichon, F., additional, Lassau, N., additional, Vanel, D., additional, Nordlinger, B., additional, Stoeckle, E., additional, Meeus, P., additional, Coindre, J.M., additional, Scoazec, J.Y., additional, Émile, J.F., additional, Ranchère, D., additional, and Blay, J.Y., additional

Published
2006
Full Text
View/download PDF

43. Analysis of 676 Cases of Ductal Carcinoma in Situ of the Breast From 1971 to 1995

Author

Tunon-de-Lara, C., primary, de-Mascarel, I., additional, Mac-Grogan, G., additional, Stöckle, E., additional, Jourdain, O., additional, Acharian, V., additional, Guegan, C., additional, Faucher, A., additional, Bussieres, E., additional, Trojani, M., additional, Bonichon, F., additional, Barreau, B., additional, Dilhuydy, M. H., additional, Dilhuydy, J. M., additional, Mauriac, L., additional, Durand, M., additional, and Avril, A., additional

Published
2001
Full Text
View/download PDF

46. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.

Author

Ravaud, A, primary, Chevreau, C, additional, Cany, L, additional, Houyau, P, additional, Dohollou, N, additional, Roché, H, additional, Soubeyran, P, additional, Bonichon, F, additional, Mihura, J, additional, Eghbali, H, additional, Tabah, I, additional, and Bui, B N, additional

Published
1998
Full Text
View/download PDF

47. Radiothérapie de l'adénocarcinome prostatique de stade T1-T2 M0. Analyse des résultats carcinologiques d'une étude multicentrique de 610 patients

Author

Rozan, R, primary, Albuisson, E, additional, Giraud, B, additional, Boiteux, J.P., additional, Dauplat, J, additional, Donnarieix, D, additional, Alcaraz, L, additional, Auvray, H, additional, Allain, Y.M., additional, Pabot Duchatelard, P, additional, Pigneux, J, additional, Richaud, P, additional, Bonichon, F, additional, Bachaud, J.M., additional, Hay, M, additional, Chenal, C, additional, Julienne, V, additional, Brune, D, additional, Mace-Lesec'h, J.J., additional, Beckendorf, V, additional, Bey, P, additional, Eschwege, F, additional, Pontvert, D, additional, Bolla, M, additional, Brochon, D, additional, Chaplain, G, additional, Lagrange, J.L., additional, Marcié, S, additional, Schumacher, C, additional, Nguyen, T.D., additional, Gérard, J.P., additional, Pommier, P, additional, Bourdain, S, additional, Castelain, B, additional, Prevost, B, additional, and Rambert, P, additional

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results